Vigil Neuro
Bruce Booth is a seasoned venture capital partner at Atlas Venture, specializing in early-stage investments within the life sciences sector since October 2005. Active in various leadership roles, Bruce currently serves as Chairman of the Board for multiple biotechnology companies, including Kymera Therapeutics, Nimbus Therapeutics, Vigil Neuroscience, Arkuda Therapeutics, HotSpot Therapeutics, and AVROBIO. Additionally, Bruce holds Board Director positions at Sionna Therapeutics and Matchpoint Therapeutics, having previously directed efforts at Magenta Therapeutics until June 2023. Academic credentials include a D.Phil. in Immunology from the University of Oxford and a B.S. in Biochemistry from Penn State University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.